Oral retinoid that selectively interacts with retinoid X receptors.
In early cutaneous T-cell disease stages IA-IIA response rate of greater than 50% associated monotherapy.
Adverse effects are hyperlipidemia, hypothyroidism, and less commonly leukopenia.
A selective retinoid X receptor modulator utilized for cutaneous T cell lymphoma.
Can selectively bind to alpha, beta, and gamma retinoid X receptors subtypes.